Current Report Filing (8-k)
July 21 2022 - 04:07PM
Edgar (US Regulatory)
0001427570 false 0001427570 2022-07-15
2022-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 15, 2022
RESHAPE LIFESCIENCES INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
1-37897 |
26-1828101 |
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
|
|
|
|
|
1001 Calle Amanecer
San Clemente,
CA
|
92673
|
|
(Address of principal executive
offices) |
(Zip Code) |
| |
|
|
|
(949)
429-6680
(Registrant’s telephone number,
including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨ |
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
|
|
¨ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
|
|
¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
|
|
|
¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
|
Title
of Class |
Trading
Symbol |
Name
of Exchange on which Registered |
|
Common stock, $0.001 par value per share |
RSLS |
The
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ¨
| Item 4.01 |
Changes in Registrant’s
Certifying Accountant. |
On
July 15, 2022, the Audit Committee of the Board of Directors
of ReShape Lifesciences Inc. (the “Company”) appointed RSM US LLP
(“RSM”) as the Company’s independent registered public accounting
firm. During the fiscal years ended December 31, 2021 and
2020, and during the subsequent interim periods through RSM’s
appointment, neither the Company nor anyone on its behalf consulted
with RSM regarding the application of accounting principles to a
specified transaction, either completed or proposed, or the type of
audit opinion that might be rendered on the Company’s financial
statements, and neither a written report nor oral advice was
provided to the Company that RSM concluded was an important factor
considered by the Company in reaching a decision as to any
accounting, auditing, or financial reporting issue, any matter that
was the subject of a “disagreement” with its former auditors or a
“reportable event,” as those terms are defined in Item 304 of
Regulation S-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
| |
RESHAPE
LIFESCIENCES INC. |
| |
|
|
| |
By: |
/s/
Tom Stankovich |
| |
|
Tom
Stankovich |
| |
|
Chief
Financial Officer |
Dated: July 21, 2022
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Dec 2022 to Jan 2023
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Jan 2022 to Jan 2023
